Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.91 USD
-0.71 (-1.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $39.00 +0.09 (0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Immunocore Holdings PLC Sponsored ADR (IMCR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$84.56 | $100.00 | $66.00 | 113.43% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Immunocore Holdings PLC Sponsored ADR comes to $84.56. The forecasts range from a low of $66.00 to a high of $100.00. The average price target represents an increase of 113.43% from the last closing price of $39.62.
Analyst Price Targets (16)
Broker Rating
Immunocore Holdings PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 16 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 5.56% of all recommendations. A month ago, Strong Buy made up 88.89%, while Buy represented 5.56%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 16 | 16 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/5/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
5/9/2024 | LadenburgThalmann | Ahu Demir | Strong Buy | Strong Buy |
5/2/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
4/29/2024 | SVB Securities | Jonathan W Chang | Not Available | Strong Buy |
4/23/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
4/11/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/15/2024 | Goldman Sachs | Rajan Sharma | Strong Buy | Strong Buy |
3/5/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
2/29/2024 | Canaccord Genuity | William Maughan | Hold | Hold |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
10/31/2023 | Robert W. Baird & Co. | Jack K Allen | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 18 |
Average Target Price | $84.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | -0.45 |